Compare 8x8 Inc (EGHT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs TransMedics Group Inc — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while TransMedics Group Inc trades at $77.5 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 8.8× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and TransMedics Group Inc for 24 Days on average.
| EGHT | TMDX | |
|---|---|---|
Market Cap | $311.98M | $2.74B |
Volume | 1,639,086 | 949,331 |
Sector | Technology | Health |
52-Week High | $2.76 | $150.42 |
52-Week Low | $1.59 | $61.99 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $578.90M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.11, down 1.4% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21 million in 2025 despite revenue of $715.07 million, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights cost-saving wins for clients and AI product growth, with a consensus analyst price target of $19.77 suggesting significant upside potential from current levels.
The outlook hinges on the company's ability to translate top-line growth into sustained profitability. While valuation multiples like a P/S of 0.42 appear attractive, a high P/E of 72 and substantial long-term debt of $338.37 million present risks. The primary opportunity is execution on its financial model to achieve positive net income, as projected for 2026.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
